ProAssurance (PRA) has wrapped up FY 2025 with fourth quarter revenue of US$259.6 million and basic EPS of US$0.65, alongside net income of US$33.4 million, giving investors a clean snapshot of its latest underwriting and investment performance. Over the last six reported quarters, the company has seen quarterly revenue range between US$259.6 million and US$289.1 million, while basic EPS has moved from a loss of US$0.11 in early 2025 to positive readings such as US$0.32 in late 2024 and US$0.65 in the most recent quarter. This sets up a results season where profit quality and consistency are front of mind. With a trailing net profit margin of 4.6%, the focus now is on how durable those margins appear in the context of softer top line expectations.

See our full analysis for ProAssurance.

With the headline numbers on the table, the next step is to see how this earnings profile aligns with the widely followed narratives around ProAssurance’s growth, margin quality, and revenue outlook.

Combined ratios show mixed underwriting picture

• Across FY 2025, reported combined ratios moved between 103.6% in Q2 2025 and 115.6% in Q1 2025, with Q3 2025 at 114.7% and a trailing 12 month combined ratio of 109.4% as of Q4 2024, signaling that underwriting costs and claims have recently been higher than premium income.
• Bears argue that higher claims severity and aggressive competition in medical liability insurance will keep underwriting margins under pressure, and the recent combined ratios above 100% align with that concern, even though:
  • Net income excluding extra items was still US$33.4 million in Q4 2025 and US$21.9 million in Q2 2025, showing that investment income and other items helped support overall profitability despite those underwriting ratios.
  • The trailing 12 month net profit margin of 4.6% indicates that, while underwriting has been tight, the company has been able to report a positive margin on the full book of business.

ProAssurance’s underwriting track record here is exactly what cautious investors are debating. If you want to see how the optimistic camp builds its case around these numbers, check out the 🐂 ProAssurance Bull Case.

Net income swings vs 5 year earnings story

• Within FY 2025, net income excluding extra items ran from a loss of US$5.8 million in Q1 2025 to a gain of US$33.4 million in Q4 2025, while trailing 12 month net income sat at US$50.9 million at Q4 2025 compared with US$52.7 million a year earlier, so the full year picture smooths out some sharp quarterly moves.
• Bears highlight the risk of volatile earnings in a concentrated medical professional liability portfolio, yet the data also show a multi year earnings build that challenges the most cautious view:
  • Over the past five years, earnings have grown at about 22.2% per year and the company moved from losses to profitability, which points to a longer term improvement behind the recent quarterly ups and downs.
  • Consensus narrative also points to renewal premium increases and re underwriting efforts improving loss ratios since 2019, which is consistent with the trailing 12 month net income of just over US$50 million despite some weak individual quarters.

Skeptics warn that these ups and downs could still matter for future returns. If you want the full cautious take built around the same figures, have a look at the 🐻 ProAssurance Bear Case.

4.6% margin and 24.7x P/E put earnings in focus

• The trailing net profit margin sits at 4.6% and the trailing 12 month Basic EPS is about US$0.99 on US$1.1b of revenue, while the current share price of US$24.47 implies a P/E of 24.7x, which is above the US insurance industry average of 12.3x but below the peer group average of 39.1x.
• Consensus narrative notes that analysts expect earnings to grow roughly 6.3% per year while revenue is expected to decline about 3.8% per year over the next three years, creating a tension between efficiency driven earnings and top line pressure:
  • The 4.6% margin on US$1.1b of trailing 12 month revenue fits with that story of modest profitability, where analysts see room for margins to improve even if reported revenue trends remain soft.
  • At the same time, the P/E of 24.7x combined with a consensus analyst price target of US$25.00 that is close to the current US$24.47 share price suggests the market is already assigning a relatively full price to those earnings expectations.

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for ProAssurance on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

If this mix of strengths and questions leaves you on the fence, spend a few minutes with the numbers yourself and decide where you stand. Then use our breakdown of 1 key reward to see what optimistic investors are focusing on.

Explore Alternatives

ProAssurance’s recent results highlight tight underwriting with combined ratios above 100% and a modest 4.6% net margin on US$1.1b of revenue, leaving little room for shocks.

If that thin buffer and earnings volatility make you uneasy, compare this profile with 78 resilient stocks with low risk scores so you can quickly focus on companies where risk indicators look more comfortable.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.